VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Kachroo, S. [1 ]
Phatak, H. [1 ]
Dorian, P. [2 ]
Kongnakorn, T. [3 ]
Lanitis, T. [4 ]
Kuznik, A. [5 ]
Mardekian, J. [6 ]
Liu, X. [7 ,8 ]
Lawrence, J. [1 ]
Lip, G. Y. [9 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Evidera, Bangkok, Thailand
[4] Evidera, London, England
[5] Celgene Corp, Summit, NJ USA
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, New York, NY USA
[8] Univ Tennessee, Coll Pharm, Knoxville, TN USA
[9] Univ Birmingham, Birmingham, W Midlands, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.661
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV67
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [1] ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA
    Giorgi, M. A.
    Caroli, C.
    Micone, P.
    Giglio, N. D.
    Aiello, E. C.
    Donato, B. M. K.
    Mould, J. F.
    Radero, G.
    Casas, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A666 - A666
  • [2] COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Chan, E.
    Li, X.
    Lau, C.
    Anand, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A866 - A867
  • [3] Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
    Hersi, Ahmad S.
    Osenenko, Katherine M.
    Kherraf, Sid Ahmed
    Aziz, Ayman Abdel
    Sambrook, Robert Joseph
    [J]. ANNALS OF SAUDI MEDICINE, 2019, 39 (04) : 265 - 278
  • [4] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [5] Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients
    Lip, Gregory Y.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Liu, Larry Z.
    Lawrence, John
    Dorian, Paul
    [J]. CIRCULATION, 2014, 130
  • [6] Cost-Effectiveness of Apixaban Compared to Other New Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation
    Rudakova, A. V.
    Tatarskiy, B. A.
    [J]. KARDIOLOGIYA, 2014, 54 (07) : 43 - 52
  • [7] A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
    Pinyol C.
    Cepeda J.M.ª
    Roldan I.
    Roldan V.
    Jimenez S.
    Gonzalez P.
    Soto J.
    [J]. Cardiology and Therapy, 2016, 5 (2) : 171 - 186
  • [8] COST-EFFECTIVENESS OF APIXABAN COMPARED TO WARFARIN AND ASPIRIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) IN THE RUSSIAN FEDERATION
    Rudakova, A., V
    Parfenov, V. A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A489 - A489
  • [9] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [10] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
12345